The findings supported the aforementioned notion and also imply that we can successfully reduce WDHD1 overexpression in bladder cancer, which may enhance the effectiveness of immune therapy and raise the likelihood that the patient will survive. This evidence concerns the gene WDHD1 and urinary bladder cancer.